November Meeting Research Articles

Shared anthropology of the Middle East: Essays on media in honor of Faye Ginsburg

AbstractThe articles in this special issue are the outcome of the panel: “Papers in Honor of Faye Ginsburg: Visual and Media Anthropology in the Middle East,” which was held virtually for the American Anthropological Association Annual Meetings of November 2021. The reach of Ginsburg's work as well as her mentorship through the creation of NYU's Graduate Program in Culture & Media has shaped the ethnography of media and visual anthropology across a diversity of geographic regions. In this particular issue, we bring together scholars of SWANA (Southwest Asia and North Africa, a term that more broadly encompasses what is often referred to as the Middle East) whose projects are deeply influenced by Ginsburg's scholarship on shared anthropology, collaborative media practices and cultural activism. This introduction includes excerpts from a conversation with Ginsburg.

November Meeting Announcements

November Meeting Announcements

November Meeting Report "Community-connected Conservation across Central Victoria" Speaker: Dr. Sophie Bickford (Central Victorian Biolinks Alliance)

November Meeting Report "Community-connected Conservation across Central Victoria" Speaker: Dr. Sophie Bickford (Central Victorian Biolinks Alliance)

Clinical data, guidelines and real-world outcomes of endovascular iliac aneurysm repair with the GORE® EXCLUDER® Iliac Branch EndoprosthesisProvision of Services for People with Vascular Disease 2021

Isolated aneurysms of the iliac arteries are extremely rare. They most frequently occur in the common iliac artery (CIA) and are least frequent in the external iliac artery (EIA).1 Most (95%) affected patients are male and the median age of diagnosis is in the seventh decade of life.2 The underlying pathology of isolated iliac artery aneurysms is similar to that of abdominal aortic aneurysms. This includes degenerative aneurysm, pseudoaneurysm, penetrating ulcer, post-dissection aneurysm mycotic aneurysm, and traumatic aneurysm.3 Unlike patients with abdominal aortic aneurysms, those with iliac artery aneurysms present with symptoms of compression of other structures, particularly the ureter, sacral plexus and iliac veins. Reported growth rate of isolated iliac artery aneurysms is similar to that of abdominal aortic aneurysms. Ruptured isolated iliac artery aneurysms are associated with significant mortality,4 which is higher when treatment is undertaken as an emergency rather than an elective surgical procedure. Effective and timely intervention is therefore essential to improve survival. The aim of surgical treatment is to exclude the aneurysm from the circulation to prevent further growth and rupture. Traditional open surgical repair (OSR) was the mainstay of treatment but is technically challenging due to the location of the aneurysms in the pelvis and a frequent prior history of abdominal aortic aneurysms.1 Endovascular repair (EVAR) of isolated iliac artery aneurysms is a less invasive alternative to OSR. It is performed by a combination of branch-vessel coil embolisation and stent grafting, and has potential advantages over OSR in reducing perioperative morbidity and mortality.5 This supplement is a report of a satellite symposium held during the Vascular Societies' Annual Scientific Meeting in November 2022. It reviews clinical data, guidelines and real-world outcomes of endovascular iliac aneurysm repair with the GORE® EXCLUDER® Iliac Branch Endoprosthesis.

November Meeting Report; Speaker, Kailee Savoia 'The Grampians Ark Project – landscape-scale predator control for threatened fauna recovery

November Meeting Report; Speaker, Kailee Savoia 'The Grampians Ark Project – landscape-scale predator control for threatened fauna recovery

November Meeting Announcements

November Meeting Announcements

Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022.

Rectal cancer is a common malignancy. The management of rectal cancer has recently evolved and has undergone a paradigm shift with the advent of treatment approaches such as total neoadjuvant therapy and the watch-and-wait approach. However, despite the recently available evidence, there is no consensus on the optimal management approach in the setting of locally advanced rectal cancer. To address some of the controversies, a joint multidisciplinary panel discussion was conducted at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting in November 2022. Members from different subspecialties formed two panels and discussed three clinical cases in a debate format. Each case represented some of the complex issues faced by clinicians in this setting. The discussion is now presented in this manuscript, which depicts the different available management approaches and reiterates the importance of a multidisciplinary approach.

November Meeting Report "Mycobacterium ulcerans (Buruli ulcer) in our native mammals in the wild" Dr. Christina McCowan (Uni Melbourne)

November Meeting Report "Mycobacterium ulcerans (Buruli ulcer) in our native mammals in the wild" Dr. Christina McCowan (Uni Melbourne)

November Meeting Announcements

November Meeting Announcements

2022 adult immunization schedule updates

Each year, the U.S. Centers for Disease Control and Prevention (CDC) releases the adult vaccine schedule. The 2022 adult vaccine schedule has several changes which will be discussed in the following manuscript. The Advisory Committee on Immunization Practices reviews the preliminary schedules usually at their October or November meetings. The following professional societies also approve the adult schedules prior to the 2022 publications: American College of Physicians (ACP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Assistants (AAPA) and the Society for Healthcare Epidemiology of America (SHEA). Once the final draft is approved by the CDC, it is published in the Morbidity and Mortality Weekly Report (MMWR) and released to healthcare providers and the general public with a cover page, tables, notes and—new for the 2022 schedule—an appendix with contraindications and precautions for the different approved vaccines.

What's New in Spine Surgery.

What's New in Spine Surgery.

November Meeting Announcements

November Meeting Announcements

The PHIRI Rapid Exchange Forum

Abstract Background The COVID-19 pandemic demanded a quick exchange of those persons and institutions who were aiding the national governments in the crisis response. Thus, devoted members of the Joint Action on Health Information already in April ‘20 started to meet regularly online to foster cross-country exchange. In these meetings partners could approach each other for questions and shared views in a trusted environment on an ad-hoc basis. This initiative became an integral part of PHIRI, allowing a quick exchange of data, indicators, good practices and experiences in the COVID-19 crisis response in a structured and efficient way. Methods The bi-weekly 1h online meetings, in a moderated, structured format, have 2 parts: 1 pre-agreed topic (chosen via a survey ex-ante to each meeting) and ad-hoc questions. Answers (backed up by evidence like national reports, guidelines, etc.) are compiled and shared via a devoted platform immediately after the meeting. Every 6 weeks there is a special edition where experts present relevant findings and recent activities in the field. Attendees are project partners, national experts (advisors to ministers and heads of agency), representatives of expert networks (e.g. Healthy Cloud), EU services (ECDC, JRC) and stakeholders (e.g. ELIXIR). Results 12 meetings took place between Nov ‘20 and April ‘21 with ±25-30 attendees. Topics covered followed a needs assessment in Europe and not surprisingly were in line with public debates at the time: November meetings concentrated around testing options whereas in early ‘21 vaccination strategies of countries were in the focus. A widely recognised outcome was a survey on the (temporary) cancellation of the use of AstraZeneca's vaccine among most EU countries. Conclusions The Rapid Exchange Forum offers a structured and highly appreciated platform for regular quick exchange of fellow countries, policy advisors, Commission services and researchers in the joint efforts to manage the COVID-19 pandemic.

Impact of financial medication assistance on medication adherence: a systematic review.

BACKGROUND: The prevalence of financial medication assistance (FMA), including patient assistance programs, coupons/copayment cards, vouchers, discount cards, and programs/pharmacy services that help patients apply for such programs, has increased. The impact of FMA on medication adherence and persistence has not been synthesized. OBJECTIVE: The primary objective of this study was to review published studies evaluating the impact of FMA on the three phases of medication adherence (initiation [or primary adherence], implementation [or secondary adherence], and discontinuation) and persistence. Among these studies, the secondary objective was to report the impact of FMA on patient out-of-pocket costs and clinical outcomes. METHODS: A systematic review was performed using MEDLINE and Web of Science. RESULTS: Of 656 articles identified, eight studies met all inclusion criteria. Seven studies examined FMA for medications treating cardiovascular diseases, while one study assessed FMA for cancer medications. Among included studies, FMA had a positive impact on medication adherence or persistence, and most measured this impact over one year or less. Of the three phases of medication adherence, implementation (5 of 8) was most commonly reported, followed by discontinuation (3 of 8), and then initiation (1 of 8). Regarding implementation, users of FMA had a higher mean medication possession ratio (MPR) than nonusers, ranging from 7 to 18 percentage points higher. The percentage of patients who discontinued medication was 7 percentage points lower in users of FMA versus nonusers for cardiovascular disease states. In one cancer study, FMA had a larger impact on initiation than discontinuation, ie, compared to nonusers, users of FMA were less likely to abandon an initial prescription (risk ratio= 0.12, 95% confidence interval [CI]: 0.08-0.18), and this effect was larger than the decreased likelihood of discontinuing the medication (hazard ratio = 0.76, 95% CI: 0.66-0.88). In 3 of 8 studies reporting on medication persistence, FMA increased the odds of medication persistence for one year ranged from 11% to 47%, depending on the study. In addition to adherence, half of the studies reported on FMA impacts on patient out-of-pocket costs and 3 of 8 studies reported on clinical outcomes. Impacts on patient out-of-pocket costs were mixed; two studies reported that out-of-pocket costs were higher for users of a coupon or a voucher versus nonusers, one study reported the opposite, and one study reported null effects. Impacts on clinical outcomes were either positive or null. CONCLUSIONS: We found that FMA has positive impacts on all phases of medication adherence as well as medication persistence over one year. Future studies should assess whether FMA has differential impacts based on phase of medication adherence and report on its longer-term (ie, beyond one year) impacts on medication adherence. DISCLOSURES: This work was sponsored by a grant from Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Hung reports past employment by Blue Cross Blue Shield Association and CVS Health and a grant from PhRMA outside of the submitted work. Zullig reports research funding from Proteus Digital Health and the PhRMA Foundation. consulting fees from Novartis. Reed reports receiving research support from Abbott Vascular, AstraZeneca, Janssen Research & Development, Monteris, PhRMA Foundation, and TESARO and consulting fees from Sanofi/Regeneron, NovoNordisk, SVC Systems, and Minomic International, Inc. Bosworth reports research grants from the PhRMA Foundation, Proteus Digital Health, Otsuka, Novo Nordisk, Sanofi, Improved Patient Outcomes, Boehinger Ingelheim, NIH, and VA, as well as consulting fees from Sanofi, Novartis, Otsuka, Abbott, Xcenda, Preventric Diagnostics, and the Medicines Company. The other authors have nothing to report. This work was presented as a poster presentation at the ESPACOMP Annual Meeting in November 2020.

Actions of the ASHP Board of Directors — Meeting of November 18, 2020

Actions of the ASHP Board of Directors — Meeting of November 18, 2020

Welcome to new Members

The ASEG extends a warm welcome to eight new Members approved by the Federal Executive at its October and November meetings (see Table). First nameLast nameOrganisationStateCountryMembership typeJe...

November Meeting Announcements

November Meeting Announcements

PROTOCOL No. 17. Meeting of the 25th November 1893.

Attended by: Honorary Member A. Ya. Krassovsky, 36 members: Batsevich, Vasten, Viridarsky, Hermonius, Goraisky, Danilovich, Dobradin, Dobrovolsky, Dranitsyn, Zheltukhin, Zamshin, Kakushkin, Lichkus, Mazurkevich, Massen, Misevich, Piotrovich, Porshnyakov, Rachinsky, Rodzevich, Ruzi, Rutkovsky, Savchenko, Sadovsky, Stelmakhovich, Stravinsky, Strogonov, Serezhnikov, Fischer A.R., Fischer B.A., Frank, Fratkin, Chernyshov, Shverdlov, Schuttenbach, Eichfuss, and 40 guests.

AMA Delegates Act on Opioid Epidemic, Widening Legalization of Cannabis

Back to table of contents Previous article ProfessionalFull AccessAMA Delegates Act on Opioid Epidemic, Widening Legalization of CannabisMark MoranMark MoranSearch for more papers by this authorPublished Online:12 Dec 2019https://doi.org/10.1176/appi.pn.2019.12b34Below is a list of some of the reports and resolutions adopted by the AMA House of Delegates at its Interim Meeting in November in San Diego:AMA Board of Trustees Report titled “Enabling Methadone Treatment of Opioid Use Disorder in Primary Care Settings.” The report calls for further research on how primary care physicians can incorporate medication treatment for addiction into their practices and asks the AMA Opioid Task Force to increase its evidence-based educational resources focused on methadone maintenance therapy and publicize those findings.AMA Board of Trustees Report titled “Opioid Mitigation.” The report calls for evaluation of outcomes and best practices by grantees of awards from the Substance Abuse and Mental Health Services Administration for the creation of local strategies to address the opioid epidemic. The report expands policy to include encouraging drug courts to use evidence-based models of care for those who the court determines would benefit from intervention rather than incarceration. It also urges state and federal policymakers to enforce applicable mental health/substance use parity laws.Resolution on Support for Veterans Courts. This resolution supports use of veterans courts as an intervention for veterans who commit criminal offenses that may be related to a neurological or psychiatric disorder.Council on Medical Education Report titled “Board Certification Changes Impact Access to Addiction Medicine Specialists.” The AMA recognizes the American Board of Preventive Medicine, as well as the American Osteopathic Association (AOA) and the AOA Bureau of Osteopathic Specialists, for developing and providing pathways for physicians to obtain certification in the subspecialty of addiction medicine, in order to improve access to care for patients with substance use disorders.Resolution on Expediting Entry of Qualified IMG Physicians to U.S. Medical Practice. This resolution asks the AMA to study and make recommendations for the best means of expediting the evaluation and credentialing of competently trained international medical graduates into medical practice in the United States.Resolution on Raising Awareness of the Public Health Impact of Cannabis. This resolution calls for the AMA to work with interested organizations to collate existing worldwide data on the public health and societal impacts and unintended consequences of legalization and/or decriminalization of cannabis for recreational and medicinal use; encourage research on the unintended consequences of legalization and decriminalization of cannabis; disseminate information on the public health impacts of legalization and decriminalization of cannabis, including possibly making links to that information available on the AMA website; and work with interested organizations to lobby Congress to allow more sites to conduct research on the risks and benefits of cannabinoid products.Resolution on Gun Violence and Mental Illness Stigma in the Media. This resolution encourages the Centers for Disease Control and Prevention, in collaboration with other public and private organizations, to develop recommendations and/or best practices for media coverage of mass shootings. This would include informed discussion of the limited data on the relationship between mental illness and gun violence and recognition of the potential for exacerbating stigma against individuals with mental illness.Resolution on Ban on Electronic Nicotine Delivery System (ENDS) Products. This resolution calls for the AMA to advocate for regulatory, legislative, and/or legal action at the federal and/or state levels to ban the sale and distribution of all e-cigarette and vaping products, with the exception of those that may be approved by the FDA for tobacco cessation purposes and made available by prescription only. The resolution also calls for the AMA to advocate for research funding to sufficiently study the safety and effectiveness of e-cigarette and vaping products for tobacco cessation purposes. ■A complete list of annotated reports and resolutions of the AMA House of Delegates Interim Meeting is posted here. ISSUES NewArchived

November Meeting Announcements

November Meeting Announcements